RESULTS NASDAQ GLOBAL MARKET: CCLD, CCLDO A healthcare technology company with 25 years of experience, delivering AI-driven, end-to-end solutions that power real-world clinical and financial transformation. © CareCloud, Inc. 2025 This presentation contains forward-looking statements within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by ...

SOMERSET, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO), a leader in healthcare technology and generative AI solutions, today announced strong financial results for the three months ended March 31, 2025. CareCloud's strategic execution, AI-driven innovation, and disciplined financial management have fueled a transformational turnaround, positioning the Company for sustained profitability and long-term growth. Management will discuss these results and the Company's 2025 growth ...

Core Insights - SOPHiA GENETICS reported a strong start to 2025 with a year-over-year revenue growth of 13%, or 15% on a constant currency basis, driven by new business signed in 2024 [3][7] - The company achieved a record adjusted gross margin of 75.7%, up 520 basis points year-over-year, indicating effective cost management and operational efficiency [3][7] - The company continues to focus on long-term growth prospects, particularly in the U.S. market, where revenue from core genomics customers grew over 30% [3][13] Financial Performance - Revenue for Q1 2025 was $17.8 million, reflecting a 13% increase from $15.8 million in Q1 2024 [7][35] - Adjusted EBITDA loss improved by 24% year-over-year to $9.8 million, demonstrating progress towards profitability [7][33] - The company reaffirms its full-year revenue guidance of $72 million to $76 million, representing a growth of approximately 10% to 17% compared to FY 2024 [7][13] Business Highlights - SOPHiA DDM™ platform performed 93,000 analyses in Q1 2025, marking an 11% year-over-year volume growth [8] - The company onboarded 33 new core genomics customers in Q1 2025, up from an average of 23 customers per quarter in 2024 [8] - Significant demand for new applications, including the Liquid Biopsy application MSK-ACCESS®, has led to a healthy pipeline of over 60 identified opportunities [9][10] Market Expansion - The company expanded its collaboration with AstraZeneca to accelerate the deployment of MSK-ACCESS® globally, now involving 30 sponsored institutions [8] - New customers were signed across various geographies, including notable institutions in Belgium, Canada, and Malaysia [8][9] - The U.S. market continues to show strong business growth, with a focus on operational excellence and sustainable growth strategies [10][11]

Core Insights - Aclarion, Inc. announced the addition of Advocate Aurora Research Institute as a site for the CLARITY trial, which aims to demonstrate the clinical and economic value of its Nociscan platform in spine surgery [1][4][5] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in identifying pain sources [1][5][8] - The Nociscan platform is the first evidence-supported SaaS solution designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine [5][8] CLARITY Trial Details - The CLARITY trial is a prospective, randomized multi-center study involving 300 patients scheduled for surgical treatment of 1- or 2-level discogenic low back pain [4] - The trial will randomize patients at a 1:1 ratio between surgeons blinded to Nociscan results and those unblinded, with the primary endpoint being the change in back pain measured on a 100mm VAS at 12 months [4][5] - The principal investigator is Dr. Nicholas Theodore from Johns Hopkins Medicine [4] Market Context - Chronic low back pain affects approximately 266 million people globally, highlighting a significant healthcare challenge [5] - Traditional imaging methods often fail to clearly identify the source of pain, which Nociscan aims to address by providing insights into disc pain [5][8]

Core Insights - Counterpart Health's research indicates that the use of Counterpart Assistant (CA) is linked to improved clinical management and reduced hospitalizations (18% lower) and readmissions (25% lower) for heart failure patients [1][6] Group 1: Study Findings - The study titled "Driving Clinical Excellence in Chronic Disease: Counterpart Assistant's Role in Heart Failure Care" highlights the positive correlation between better clinical care and lower hospitalizations for congestive heart failure (CHF) patients who have a relationship with a Primary Care Physician (PCP) using CA [1][2] - CA empowers healthcare providers by offering timely, data-driven insights, which lead to significant improvements in patient outcomes, particularly in chronic disease management [2][3] - The technology focuses on proactive interventions and longitudinal care, addressing the high burden of CHF among Medicare enrollees, who experience the highest readmission rates [2] Group 2: Company Overview - Counterpart Health, a subsidiary of Clover Health Investments, is an AI-powered physician enablement platform that aims to enhance patient outcomes and reduce healthcare costs through its flagship software, Counterpart Assistant [5] - The company has conducted multiple retrospective analyses to measure CA's clinical impact, previously focusing on Diabetes and Chronic Kidney Disease, as well as Medication Adherence [3][5] - The relationship with a CA provider is associated with better clinical outcomes, including increased outpatient cardiologist visits and in-home care management for CHF patients [6]

Core Insights - Amwell, a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, announced its financial results for the first quarter ended March 31, 2025 [1] Company Overview - Amwell offers a single, comprehensive, technology-enabled care platform for payers and health systems, enhancing patient access to convenient, affordable, and effective care [3] - The platform includes software and services that support various clinical programs, providing unified, personalized access to diversified clinical programs across the care continuum [3] - Amwell has been operational for almost two decades, serving some of the largest healthcare organizations in the U.S. and worldwide, enabling care for millions of patients [3]

Core Insights - OptimizeRx Corp. has published its 2025 Environmental, Social, and Governance (ESG) report, highlighting its commitment to corporate responsibility and stakeholder engagement [1][3] - The company improved its Institutional Shareholder Services (ISS) ESG rating from the seventh decile to the first decile, achieving prime status [3] Governance - The Board of Directors and the Nominating & Governance Committee are actively involved in aligning business strategies with corporate governance policies [8] - A double-materiality survey identified key stakeholder concerns in three areas: Data Protection, Ethics and Governance, and Human Capital [8] Planet - The 2025 ESG report includes enhanced disclosures on Scope 1 emissions and additional reporting on individual greenhouse gases [5] People - The company emphasizes impartiality in employment practices and aims to foster a culture of respect and inclusivity [9] - Initiatives such as the SPARK employee recognition program and a Competency Model have been introduced to enhance employee engagement and career progression [9] Prosperity - The Dynamic Audience Activation Platform (DAAP) has seen strong adoption, providing AI-enabled marketing solutions that connect life sciences, healthcare professionals, and patients [15] - The integration of Healthy Offers, Inc. enhances the company's data and analytics capabilities, expanding its stakeholder engagement [15]

Core Viewpoint - HealthLynked Corp has announced significant enhancements to its appointment booking capabilities, aimed at improving patient access to healthcare services through its platform [1][8]. Group 1: Appointment Booking Enhancements - The new system allows HealthLynked Concierge Members to request appointments with out-of-network providers, specifying preferred days and times [2][6]. - Concierge Members can now request appointments based on medical specialty without selecting a specific provider, streamlining the process for patients [2][6]. - The appointment booking interface has been updated to include common reasons for visits by medical specialty, allowing patients to provide clear information to providers [2][4]. Group 2: Enhanced Provider Review System - HealthLynked has introduced an enhanced provider review system, enabling users to leave detailed feedback through star ratings and narrative reviews [3][5]. - The accumulation of provider reviews is expected to improve transparency in healthcare options and encourage providers to enhance care quality [4][5]. - This system empowers patients to make informed decisions based on verified experiences from other users, improving overall healthcare experiences [4][5]. Group 3: Overall Impact on Patient Experience - The enhancements aim to streamline the healthcare experience, making it easier for patients to find trusted providers quickly [7]. - HealthLynked's mission is to connect patients with optimal healthcare solutions efficiently, with the latest upgrades expanding access to care [8][9].

Financial Data and Key Metrics Changes - In Q1 2025, GAAP net income was $5.2 million or $0.25 per diluted share, up from $4.2 million or $0.21 per diluted share in Q1 2024 [22] - Total GAAP revenue for Q1 2025 was $36.3 million, an increase of over 7% from $33.9 million in the prior quarter and nearly 4% from $34.9 million in Q1 2024 [23] - Adjusted EBITDA totaled $8.2 million, reflecting a nearly 9% increase from the same quarter in 2024 [28] Business Line Data and Key Metrics Changes - Software revenue reached $17.8 million, up 9.2% from the prior year quarter, while wireless revenue was $18.5 million, nearly flat compared to Q1 2024 [23] - Professional services revenue was $5.8 million, up nearly 44% from $4 million in Q1 2024, with managed services revenue totaling $1.3 million, representing over 22% of total professional services revenue [26] - Software backlog increased by more than 15% year over year, indicating strong future revenue potential [42] Market Data and Key Metrics Changes - The company maintains the largest paging network in the United States, serving over 2,200 hospitals [12] - Wireless average revenue per unit (ARPU) increased by 4.4% year over year to $824, driven by pricing actions and sales of new products [23] Company Strategy and Development Direction - The company aims to generate cash and return capital to shareholders while investing in business growth, focusing on four strategic tenets: investment in wireless and software solutions, revenue growth, disciplined expense management, and stockholder-friendly capital allocation [10][9] - The company is committed to maintaining a strong position in healthcare communications, leveraging its established solutions and customer base to create shareholder value [10][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's performance and reiterated guidance for 2025, expecting total revenue to range from $134 million to $142 million [31] - The company believes that current macroeconomic uncertainties will not materially impact revenue or supply chain, maintaining a positive outlook for the healthcare industry [14] Other Important Information - The company plans to invest between $11 million and $12 million in product research and development in 2025 to fuel future software revenue growth [9] - The company has returned over $700 million to shareholders over the past 20 years through dividends and share repurchases [9] Q&A Session Summary Question: Is there any seasonality with the larger 7-figure contracts? - Management noted no seasonality observed, with a positive trend in contract signings [36][37] Question: What drove the strong wireless product revenue? - The increase was primarily due to a price increase for unreturned pagers, expected to yield an annualized benefit of about $1 million [38][39] Question: What drove the improvement in gross margin? - Gross margin improved due to strong revenue performance, but fluctuations are expected based on revenue dynamics [40][41] Question: What is the conversion timeline for the software backlog? - Approximately half of the backlog is services, which typically convert over a 9 to 15-month period [42][43] Question: What was the experience at the HIMSS conference? - The conference was better than the previous year, with a focused approach leading to successful customer engagements [48][49] Question: What is the strategy for professional services? - The focus is on managed services, providing fixed costs for customers and improving revenue recognition [51][52] Question: Are the two new logos significant customers? - Both new customers are meaningful wins that the company has pursued for some time [58][60]

Financial Data and Key Metrics Changes - Waystar reported Q1 revenue of $256 million, reflecting a 14% year-over-year increase and an adjusted EBITDA of $108 million, which is a 16% increase year-over-year [7][26][19] - The adjusted EBITDA margin was 42%, aligning with the long-term target of approximately 40% [29][19] - The net leverage ratio at the end of Q1 was 2.5 times, indicating a decrease of approximately a quarter turn in the quarter [30] Business Line Data and Key Metrics Changes - Subscription revenue increased by 18% year-over-year and 3% sequentially, while volume-based revenue grew by 11% year-over-year, with an adjusted growth rate of approximately 12% [27][28] - The number of clients generating over $100,000 in trailing twelve-month revenue increased by 15% year-over-year to 1,244 clients [11] Market Data and Key Metrics Changes - Waystar serves over a million US-based providers across various care settings, indicating a broad market presence [8] - The company reported a 114% net revenue retention rate, which is above the typical range of 108% to 110% experienced over the past three years [26][11] Company Strategy and Development Direction - Waystar is focused on sustainable revenue growth, operational profitability, and innovation through its cloud-based software platform [10][19] - The company is pursuing a strategic software product roadmap that emphasizes scale, automation, and substantial ROI, including the recent launch of Altitude AI [13][66] - Waystar aims to leverage generative AI to enhance operational efficiency and reduce costs for clients, positioning itself as a leader in the healthcare payments sector [86][90] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong performance despite macroeconomic volatility, citing the recession-resistant nature of its business model [8][30] - The company anticipates no major impact from potential new healthcare policies in 2025, suggesting that reliance on software platforms like Waystar's will likely increase [9] Other Important Information - Waystar's software platform is designed to help providers optimize cash flow and reduce administrative costs, which is critical in challenging economic conditions [8][9] - The company has maintained high cybersecurity standards and regularly audits its platform against industry-leading frameworks [19] Q&A Session Summary Question: Breakdown of Q1 outperformance and guidance components - Management indicated that strong patient payment utilization contributed to Q1 performance, with 98% of revenue generally coming from contracted solutions [34][35] Question: Drivers of net revenue retention at 114% - The retention rate was influenced by robust bookings from revenue cycle solutions and strong client advocacy leading to cross-sell opportunities [40][41] Question: Trends in utilization and seasonality - Management noted that utilization has trended above historical averages, benefiting the business model, with minimal seasonality in provider solutions [45][51] Question: Impact of security and implementation time on sales cycles - The company has seen strong demand and robust RFP activity, with clients prioritizing mission-critical solutions during economic uncertainty [53][56] Question: RFP activity and tariff impact - Management reassured that Waystar has no direct exposure to tariffs and continues to see strong demand for its AI-driven solutions [59][62] Question: AI's impact on market share and client relationships - The company views the trend of bringing outsourced RCM back in-house as beneficial, allowing for expansion of addressable market opportunities [84][90] Question: M&A strategy post-leverage target achievement - Waystar is actively pursuing M&A opportunities that align with its business model, focusing on technology, people, and clients that fit its objectives [101][104]